Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000522419 | SCV000617026 | uncertain significance | not provided | 2018-04-03 | criteria provided, single submitter | clinical testing | The V95I variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The V95I variant was not observed in approximately 6,500 individuals of European and African American ancestry in an external variant database, indicating it is not a common benign variant in these populations. The V95I variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position where amino acids with similar properties to Valine are tolerated across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. In summary, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Invitae | RCV000640932 | SCV000762537 | likely benign | Creatine transporter deficiency | 2023-10-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002438252 | SCV002746527 | likely benign | Inborn genetic diseases | 2018-05-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |